From an idea, which took more than a year to form, to completing and submitting my #PhD thesis thanks to my fascinating #mentor and my support Dunja Aksentijevic Ricciarelli 🫶 Five years of commitment work and research has finally come to an end. #womeninSTEM #interventionalcardiology

🫶

#NewProfilePic

I’ll be speaking in a session at #EuroPCR in Paris 20-23 May. Join me if you want to discuss more about ➡️DCBs in de novo lesions. Looking forward to seeing some familiar faces and making new connections. It is always a privilege to be a #PCRpresenter PCRonline 🫀 #womeninSTEM

Thank you #EuroPCR for great organisation and a chance to present my work in Paris 🇫🇷It was a great pleasure meeting with peers and discussing about DCBs in de novo lesions. 🫀 PCRonline 🫀 #WomenInSTEM

Great news today on my birthday. ▶️Our paper is published in Springer Nature Cardiovascular Diabetology! 🧁Great birthday present. Huge thanks to my inspiration, mentor and friend Dunja Aksentijevic Ricciarelli 🫶 Megan Young #womeninstem cardiab.biomedcentral.com/articles/10.11…

🚨T2D in 🚺 worsens STEMI outcomes beyond door-to-balloon delays & mirrors the HFpEF cardiometabolic phenotype in female db/db mice. Sex-specific strategies are urgently needed! Congrats to study co-leads Ivana Iveljic Megan Young BMC William Harvey Research Institute doi.org/10.1186/s12933…

Proud of Dr Ivana Iveljić Ivana Iveljic her patient-centred, rigorous PhD work is now online! We report silent, proximal CAD years after fluoropyrimidines in CRC survivors with real implications for survivorship care. 🩺🫀 👉🏻medrxiv.org/content/10.110… William Harvey Research Institute Barts and The London, Queen Mary

"I've done it!" On 16 September 1977, Andreas Grüntzig made history: he carried out the first #angioplasty, and changed the lives of millions of patients forever. Standing on the shoulders of the giants that came before him, his vision and determination drove an entire new

I wouldn’t exactly call myself a black belt in beta-blockers, but with all this talk of superiority, "non-superiority," and "non-non-inferiority," it’s really enough to get confused. If I interpret correctly the avalanche of trials from the past year, accompanied by the